Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response

T. Kalincik, A. Manouchehrinia, L. Sobisek, V. Jokubaitis, T. Spelman, D. Horakova, E. Havrdova, M. Trojano, G. Izquierdo, A. Lugaresi, M. Girard, A. Prat, P. Duquette, P. Grammond, P. Sola, R. Hupperts, F. Grand'Maison, E. Pucci, C. Boz, R....

. 2017 ; 140 (9) : 2426-2443.

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016271

Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis; however, treatment response varies greatly among patients. Comprehensive predictive models of individual treatment response are lacking. Our aims were: (i) to develop predictive algorithms for individual treatment response using demographic, clinical and paraclinical predictors in patients with multiple sclerosis; and (ii) to evaluate accuracy, and internal and external validity of these algorithms. This study evaluated 27 demographic, clinical and paraclinical predictors of individual response to seven disease-modifying therapies in MSBase, a large global cohort study. Treatment response was analysed separately for disability progression, disability regression, relapse frequency, conversion to secondary progressive disease, change in the cumulative disease burden, and the probability of treatment discontinuation. Multivariable survival and generalized linear models were used, together with the principal component analysis to reduce model dimensionality and prevent overparameterization. Accuracy of the individual prediction was tested and its internal validity was evaluated in a separate, non-overlapping cohort. External validity was evaluated in a geographically distinct cohort, the Swedish Multiple Sclerosis Registry. In the training cohort (n = 8513), the most prominent modifiers of treatment response comprised age, disease duration, disease course, previous relapse activity, disability, predominant relapse phenotype and previous therapy. Importantly, the magnitude and direction of the associations varied among therapies and disease outcomes. Higher probability of disability progression during treatment with injectable therapies was predominantly associated with a greater disability at treatment start and the previous therapy. For fingolimod, natalizumab or mitoxantrone, it was mainly associated with lower pretreatment relapse activity. The probability of disability regression was predominantly associated with pre-baseline disability, therapy and relapse activity. Relapse incidence was associated with pretreatment relapse activity, age and relapsing disease course, with the strength of these associations varying among therapies. Accuracy and internal validity (n = 1196) of the resulting predictive models was high (>80%) for relapse incidence during the first year and for disability outcomes, moderate for relapse incidence in Years 2-4 and for the change in the cumulative disease burden, and low for conversion to secondary progressive disease and treatment discontinuation. External validation showed similar results, demonstrating high external validity for disability and relapse outcomes, moderate external validity for cumulative disease burden and low external validity for conversion to secondary progressive disease and treatment discontinuation. We conclude that demographic, clinical and paraclinical information helps predict individual response to disease-modifying therapies at the time of their commencement.

Amiri Hospital P O Box 1661 Qurtoba Kuwait 73767 Kuwait

Assaf Harofeh Medical Center Zerifin Beer Yaakov 70100 Israel

Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino Contrada Amoretta Avellino 83100 Italy

Azienda Sanitaria Unica Regionale Marche AV3 Via Santa Lucia 2 Macerata 62100 Italy

Brain and Mind Centre University of Sydney 100 Mallett Camperdown 2050 Australia

C Mondino National Neurological Institute via Mondino 2 Pavia 27100 Italy

Centre de réadaptation déficience physique Chaudière Appalache 9500 blvd Centre Hospitalier Levis G6X 0A1 Canada

CHUM and Universite de Montreal Montreal Canada

Cliniques Universitaires Saint Luc avenue Hippocrate 10 UCL10 80 Brussels 1200 BXL Belgium

CORe Department of Medicine University of Melbourne 300 Grattan St Melbourne 3050 Australia Department of Neurology Royal Melbourne Hospital 300 Grattan St Melbourne 3050 Australia

Department of Clinical Neuroscience Karolinska Institutet Stockholm SE 17177 Sweden

Department of Neurology and Center of Clinical Neuroscience General University Hospital and Charles University Prague Katerinska 30 Prague 12808 Czech Republic

Department of Neurology and Center of Clinical Neuroscience General University Hospital and Charles University Prague Katerinska 30 Prague 12808 Czech Republic Department of Statistics and Probability University of Economics Prague Winston Churchill Sq 1938 4 Prague 13067 Czech Republic

Department of Neurology Royal Melbourne Hospital 300 Grattan St Melbourne 3050 Australia Department of Medicine University of Melbourne 300 Grattan St Melbourne 3050 Australia

Department of Neurology Royal Melbourne Hospital 300 Grattan St Melbourne 3050 Australia Department of Medicine University of Melbourne 300 Grattan St Melbourne 3050 Australia Department of Neurology Box Hill Hospital Monash University Melbourne Australia

Department of Neuroscience Imaging and Clinical Sciences University 'G d'Annunzio' Via dei Vestini Chieti 66100 Italy Department of Biomedical and Neuromotor Sciences University of Bologna Via dei Vestini Bologna 66100 Italy

Flinders Medical Centre Flinders Drive Adelaide 5042 Australia

Groene Hart ziekenhuis bleulandweg 10 Gouda 2800 BB The Netherlands

Hopital Notre Dame 1560 Sherbrooke East Montreal H2L 4M1 Canada

Hospital de Galdakao Usansolo Barrio Labeaga s n Galdakao 48660 Spain

Hospital Donostia Paseo de Begiristain San Sebastián 20014 Spain

Hospital Germans Trias i Pujol Crtra de Canyet s n Badalona 8916 Spain

Hospital Italiano Guise 1870 Buenos Aires 1425 Argentina

Hospital Universitario La Paz Paseo de la Castellana 261 Madrid 28050 Spain

Hospital Universitario Virgen Macarena Amador de los Rios 48 50 4a Sevilla 41003 Spain

INEBA Institute of Neuroscience Buenos Aires Guardia Vieja 4435 Buenos Aires C1192AAW Argentina

Isfahan University of Medical Sciences Soffeh St Isfahan 81744 Iran

Jahn Ferenc Teaching Hospital Köves u 1 Budapest 1101 Hungary

Jewish General Hospital 3755 Cote Sainte Catherine Montreal J7A 4T8 Canada

KTU Medical Faculty Farabi Hospital Karadeniz Technical University Trabzon 61080 Turkey

Liverpool Hospital Elizabeth St Liverpool 21 Australia

Nemocnice Jihlava Vrchlickeho 59 Jihlava 58633 Czech Republic

Neuro Rive Sud 4896 boul Taschereau suite 250 Greenfield Park J4V 2J2 Canada

Nuovo Ospedale Civile Sant'Agostino Estense via giardini 1355 Modena 41100 Italy

Ondokuz Mayis University Medical Faculty Kurupelit Samsun 55160 Turkey

Ospedali Riuniti di Salerno Via s Leonardo Salerno 84100 Italy

Royal Brisbane and Women's Hospital 33 North Street Spring Hill QLD 4000 Australia

University of Bari Via Calefati 53 Bari 70122 Italy

University of Florence Viale Morgagni 85 Florence 50134 Italy

University of Newcastle Lookout Road Newcastle 2305 Australia

University of Parma Via Gramsci 14 Parma 43100 Italy

Westmead Hospital Hawkesbury Rd Sydney 2145 Australia

Zuyderland Ziekenhuis Walramstraat 23 Sittard 6131 BK The Netherlands

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016271
003      
CZ-PrNML
005      
20180518101236.0
007      
ta
008      
180515s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/brain/awx185 $2 doi
035    __
$a (PubMed)29050389
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Kalincik, Tomas $u CORe, Department of Medicine, University of Melbourne, 300 Grattan St, Melbourne, 3050, Australia. Department of Neurology, Royal Melbourne Hospital, 300 Grattan St, Melbourne, 3050, Australia.
245    10
$a Towards personalized therapy for multiple sclerosis: prediction of individual treatment response / $c T. Kalincik, A. Manouchehrinia, L. Sobisek, V. Jokubaitis, T. Spelman, D. Horakova, E. Havrdova, M. Trojano, G. Izquierdo, A. Lugaresi, M. Girard, A. Prat, P. Duquette, P. Grammond, P. Sola, R. Hupperts, F. Grand'Maison, E. Pucci, C. Boz, R. Alroughani, V. Van Pesch, J. Lechner-Scott, M. Terzi, R. Bergamaschi, G. Iuliano, F. Granella, D. Spitaleri, V. Shaygannejad, C. Oreja-Guevara, M. Slee, R. Ampapa, F. Verheul, P. McCombe, J. Olascoaga, MP. Amato, S. Vucic, S. Hodgkinson, C. Ramo-Tello, S. Flechter, E. Cristiano, C. Rozsa, F. Moore, J. Luis Sanchez-Menoyo, M. Laura Saladino, M. Barnett, J. Hillert, H. Butzkueven, . ,
520    9_
$a Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis; however, treatment response varies greatly among patients. Comprehensive predictive models of individual treatment response are lacking. Our aims were: (i) to develop predictive algorithms for individual treatment response using demographic, clinical and paraclinical predictors in patients with multiple sclerosis; and (ii) to evaluate accuracy, and internal and external validity of these algorithms. This study evaluated 27 demographic, clinical and paraclinical predictors of individual response to seven disease-modifying therapies in MSBase, a large global cohort study. Treatment response was analysed separately for disability progression, disability regression, relapse frequency, conversion to secondary progressive disease, change in the cumulative disease burden, and the probability of treatment discontinuation. Multivariable survival and generalized linear models were used, together with the principal component analysis to reduce model dimensionality and prevent overparameterization. Accuracy of the individual prediction was tested and its internal validity was evaluated in a separate, non-overlapping cohort. External validity was evaluated in a geographically distinct cohort, the Swedish Multiple Sclerosis Registry. In the training cohort (n = 8513), the most prominent modifiers of treatment response comprised age, disease duration, disease course, previous relapse activity, disability, predominant relapse phenotype and previous therapy. Importantly, the magnitude and direction of the associations varied among therapies and disease outcomes. Higher probability of disability progression during treatment with injectable therapies was predominantly associated with a greater disability at treatment start and the previous therapy. For fingolimod, natalizumab or mitoxantrone, it was mainly associated with lower pretreatment relapse activity. The probability of disability regression was predominantly associated with pre-baseline disability, therapy and relapse activity. Relapse incidence was associated with pretreatment relapse activity, age and relapsing disease course, with the strength of these associations varying among therapies. Accuracy and internal validity (n = 1196) of the resulting predictive models was high (>80%) for relapse incidence during the first year and for disability outcomes, moderate for relapse incidence in Years 2-4 and for the change in the cumulative disease burden, and low for conversion to secondary progressive disease and treatment discontinuation. External validation showed similar results, demonstrating high external validity for disability and relapse outcomes, moderate external validity for cumulative disease burden and low external validity for conversion to secondary progressive disease and treatment discontinuation. We conclude that demographic, clinical and paraclinical information helps predict individual response to disease-modifying therapies at the time of their commencement.
650    _2
$a dospělí $7 D000328
650    12
$a algoritmy $7 D000465
650    _2
$a databáze faktografické $7 D016208
650    _2
$a demografie $7 D003710
650    _2
$a posuzování pracovní neschopnosti $7 D004185
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a předpověď $x metody $7 D005544
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $x terapeutické užití $7 D007166
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a roztroušená skleróza $x diagnóza $x farmakoterapie $7 D009103
650    _2
$a individualizovaná medicína $x metody $7 D057285
650    _2
$a prognóza $7 D011379
650    _2
$a recidiva $7 D012008
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a rizikové faktory $7 D012307
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Manouchehrinia, Ali $u Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, SE-17177, Sweden.
700    1_
$a Sobisek, Lukas $u Department of Neurology and Center of Clinical Neuroscience, General University Hospital and Charles University in Prague, Katerinska 30, Prague, 12808, Czech Republic. Department of Statistics and Probability, University of Economics in Prague, Winston Churchill Sq 1938/4, Prague, 13067, Czech Republic.
700    1_
$a Jokubaitis, Vilija $u Department of Neurology, Royal Melbourne Hospital, 300 Grattan St, Melbourne, 3050, Australia. Department of Medicine, University of Melbourne, 300 Grattan St, Melbourne, 3050, Australia.
700    1_
$a Spelman, Tim $u Department of Neurology, Royal Melbourne Hospital, 300 Grattan St, Melbourne, 3050, Australia. Department of Medicine, University of Melbourne, 300 Grattan St, Melbourne, 3050, Australia.
700    1_
$a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, General University Hospital and Charles University in Prague, Katerinska 30, Prague, 12808, Czech Republic.
700    1_
$a Havrdova, Eva $u Department of Neurology and Center of Clinical Neuroscience, General University Hospital and Charles University in Prague, Katerinska 30, Prague, 12808, Czech Republic.
700    1_
$a Trojano, Maria $u University of Bari, Via Calefati 53, Bari, 70122, Italy.
700    1_
$a Izquierdo, Guillermo $u Hospital Universitario Virgen Macarena, Amador de los Rios 48-50. 4a, Sevilla, 41003, Spain.
700    1_
$a Lugaresi, Alessandra $u Department of Neuroscience, Imaging and Clinical Sciences, University 'G. d'Annunzio', Via dei Vestini, Chieti, 66100, Italy. Department of Biomedical and Neuromotor Sciences, University of Bologna, Via dei Vestini, Bologna, 66100, Italy.
700    1_
$a Girard, Marc $u Hopital Notre Dame, 1560 Sherbrooke East, Montreal, H2L 4M1, Canada; CHUM and Universite de Montreal, Montreal, Canada.
700    1_
$a Prat, Alexandre $u Hopital Notre Dame, 1560 Sherbrooke East, Montreal, H2L 4M1, Canada; CHUM and Universite de Montreal, Montreal, Canada.
700    1_
$a Duquette, Pierre $u Hopital Notre Dame, 1560 Sherbrooke East, Montreal, H2L 4M1, Canada; CHUM and Universite de Montreal, Montreal, Canada.
700    1_
$a Grammond, Pierre $u Centre de réadaptation déficience physique Chaudière-Appalache, 9500 blvd Centre-Hospitalier, Levis, G6X 0A1, Canada.
700    1_
$a Sola, Patrizia $u Nuovo Ospedale Civile Sant'Agostino/Estense, via giardini 1355, Modena, 41100, Italy.
700    1_
$a Hupperts, Raymond $u Zuyderland Ziekenhuis, Walramstraat 23, Sittard, 6131 BK, The Netherlands.
700    1_
$a Grand'Maison, Francois $u Neuro Rive-Sud, 4896 boul. Taschereau, suite 250, Greenfield Park, J4V 2J2, Canada.
700    1_
$a Pucci, Eugenio $u Azienda Sanitaria Unica Regionale Marche - AV3, Via Santa Lucia 2, Macerata, 62100, Italy.
700    1_
$a Boz, Cavit $u KTU Medical Faculty Farabi Hospital, Karadeniz Technical University, Trabzon, 61080, Turkey.
700    1_
$a Alroughani, Raed $u Amiri Hospital, P.O. Box 1661. Qurtoba, Kuwait, 73767, Kuwait.
700    1_
$a Van Pesch, Vincent $u Cliniques Universitaires Saint-Luc, avenue Hippocrate, 10 UCL10/80, Brussels, 1200 BXL, Belgium.
700    1_
$a Lechner-Scott, Jeannette $u University of Newcastle, Lookout Road, Newcastle, 2305, Australia.
700    1_
$a Terzi, Murat $u Ondokuz Mayis University, Medical Faculty, Kurupelit, Samsun, 55160, Turkey.
700    1_
$a Bergamaschi, Roberto $u C. Mondino National Neurological Institute, via Mondino 2, Pavia, 27100, Italy.
700    1_
$a Iuliano, Gerardo $u Ospedali Riuniti di Salerno, Via s. Leonardo, Salerno, 84100, Italy.
700    1_
$a Granella, Franco $u University of Parma, Via Gramsci, 14, Parma, 43100, Italy.
700    1_
$a Spitaleri, Daniele $u Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Contrada Amoretta, Avellino, 83100, Italy.
700    1_
$a Shaygannejad, Vahid $u Isfahan University of Medical Sciences, Soffeh St, Isfahan, 81744, Iran.
700    1_
$a Oreja-Guevara, Celia $u Hospital Universitario La Paz, Paseo de la Castellana 261, Madrid, 28050, Spain.
700    1_
$a Slee, Mark $u Flinders Medical Centre, Flinders Drive, Adelaide, 5042, Australia.
700    1_
$a Ampapa, Radek $7 mzk2018987225 $u Nemocnice Jihlava, Vrchlickeho 59, Jihlava, 58633, Czech Republic.
700    1_
$a Verheul, Freek $u Groene Hart ziekenhuis, bleulandweg 10, Gouda, 2800 BB, The Netherlands.
700    1_
$a McCombe, Pamela $u Royal Brisbane and Women's Hospital, 33 North Street, Spring Hill, QLD 4000, Australia.
700    1_
$a Olascoaga, Javier $u Hospital Donostia, Paseo de Begiristain, San Sebastián, 20014, Spain.
700    1_
$a Amato, Maria Pia $u University of Florence, Viale Morgagni 85, Florence, 50134, Italy.
700    1_
$a Vucic, Steve $u Westmead Hospital, Hawkesbury Rd, Sydney, 2145, Australia.
700    1_
$a Hodgkinson, Suzanne $u Liverpool Hospital, Elizabeth St, Liverpool, 21, Australia.
700    1_
$a Ramo-Tello, Cristina $u Hospital Germans Trias i Pujol, Crtra de Canyet s/n, Badalona, 8916, Spain.
700    1_
$a Flechter, Shlomo $u Assaf Harofeh Medical Center, Zerifin, Beer-Yaakov, 70100, Israel.
700    1_
$a Cristiano, Edgardo $u Hospital Italiano, Guise 1870, Buenos Aires, 1425, Argentina.
700    1_
$a Rozsa, Csilla $u Jahn Ferenc Teaching Hospital, Köves u. 1., Budapest, 1101, Hungary.
700    1_
$a Moore, Fraser $u Jewish General Hospital, 3755 Cote-Sainte-Catherine, Montreal, J7A 4T8, Canada.
700    1_
$a Luis Sanchez-Menoyo, Jose $u Hospital de Galdakao-Usansolo, Barrio Labeaga s.n., Galdakao, 48660, Spain.
700    1_
$a Laura Saladino, Maria $u INEBA - Institute of Neuroscience Buenos Aires, Guardia Vieja 4435, Buenos Aires, C1192AAW, Argentina.
700    1_
$a Barnett, Michael $u Brain and Mind Centre, University of Sydney, 100 Mallett, Camperdown, 2050, Australia.
700    1_
$a Hillert, Jan $u Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, SE-17177, Sweden.
700    1_
$a Butzkueven, Helmut $u Department of Neurology, Royal Melbourne Hospital, 300 Grattan St, Melbourne, 3050, Australia. Department of Medicine, University of Melbourne, 300 Grattan St, Melbourne, 3050, Australia. Department of Neurology, Box Hill Hospital, Monash University, Melbourne, Australia.
700    1_
$a ,
773    0_
$w MED00009356 $t Brain a journal of neurology $x 1460-2156 $g Roč. 140, č. 9 (2017), s. 2426-2443
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29050389 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180518101413 $b ABA008
999    __
$a ok $b bmc $g 1299895 $s 1013111
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 140 $c 9 $d 2426-2443 $i 1460-2156 $m Brain $n Brain $x MED00009356
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Možnosti archivace